Nissay Asset Management Corp Japan Has $12.48 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Nissay Asset Management Corp Japan raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 23,713 shares of the company’s stock after acquiring an additional 1,056 shares during the period. Nissay Asset Management Corp Japan’s holdings in IDEXX Laboratories were worth $12,483,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $26,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories in the 2nd quarter valued at $25,000. Elevation Wealth Partners LLC boosted its stake in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the period. Finally, Wormser Freres Gestion boosted its stake in IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 47 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Barclays cut their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. UBS Group increased their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Stock Up 1.8%

IDEXX Laboratories stock opened at $554.99 on Friday. The company has a market cap of $43.72 billion, a P/E ratio of 39.03, a price-to-earnings-growth ratio of 2.96 and a beta of 1.54. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The company has a fifty day simple moving average of $559.01 and a 200 day simple moving average of $573.80. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period in the previous year, the business earned $3.50 EPS. The company’s revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.